Industry
Biotechnology
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Loading...
Open
58.00
Mkt cap
3.7B
Volume
456K
High
60.13
P/E Ratio
-13.88
52-wk high
68.58
Low
57.59
Div yield
N/A
52-wk low
31.52
Portfolio Pulse from
November 13, 2024 | 11:45 pm
Portfolio Pulse from
November 13, 2024 | 9:15 pm
Portfolio Pulse from
November 06, 2024 | 4:00 am
Portfolio Pulse from
November 05, 2024 | 9:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 9:40 am
Portfolio Pulse from Benzinga Insights
October 25, 2024 | 2:01 pm
Portfolio Pulse from Benzinga Newsdesk
October 25, 2024 | 11:10 am
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 10:07 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.